MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584469 | Name: ML 351
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML 351 is a selective 12/15 LOX inhibitor that is active in vivo.

Chemical Structure

ML 351
ML 351
CAS#847163-28-4

Theoretical Analysis

MedKoo Cat#: 584469

Name: ML 351

CAS#: 847163-28-4

Chemical Formula: C15H11N3O

Exact Mass: 249.0902

Molecular Weight: 249.27

Elemental Analysis: C, 72.28; H, 4.45; N, 16.86; O, 6.42

Price and Availability

Size Price Availability Quantity
5mg USD 340.00
25mg USD 900.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ML 351; ML-351; ML351
IUPAC/Chemical Name
5-(Methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile
InChi Key
DYXYXTDIFMDJIR-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H11N3O/c1-17-15-13(9-16)18-14(19-15)12-8-4-6-10-5-2-3-7-11(10)12/h2-8,17H,1H3
SMILES Code
N#CC1=C(NC)OC(C2=C3C=CC=CC3=CC=C2)=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM.
In vitro activity:
In mouse islets, incubation with ML351 improved glucose-stimulated insulin secretion in the presence of proinflammatory cytokines and triggered gene expression pathways responsive to oxidative stress and cell death. Consistent with a role for 12/15-LOX in promoting oxidative stress, its chemical inhibition reduced production of reactive oxygen species in both mouse and human islets in vitro. Reference: Diabetes. 2017 Nov;66(11):2875-2887. https://pubmed.ncbi.nlm.nih.gov/28842399/
In vivo activity:
Rats were subjected to embolic middle cerebral artery occlusion with 2 or 3 hr ischemia and tPA infusion, with or without ML351. ML351 significantly reduced tPA related hemorrhage after stroke without affecting its thrombolytic efficacy. ML351 also reduced blood-brain barrier disruption and improved preservation of junction proteins. Reference: J Neurochem. 2021 May;157(3):586-598. https://pubmed.ncbi.nlm.nih.gov/33481248/
Solvent mg/mL mM comments
Solubility
DMF 25.0 100.29
DMSO 51.2 205.53
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 249.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hernandez-Perez M, Chopra G, Fine J, Conteh AM, Anderson RM, Linnemann AK, Benjamin C, Nelson JB, Benninger KS, Nadler JL, Maloney DJ, Tersey SA, Mirmira RG. Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. Diabetes. 2017 Nov;66(11):2875-2887. doi: 10.2337/db17-0215. Epub 2017 Aug 25. PMID: 28842399; PMCID: PMC5652601. 2. Rai G, Joshi N, Jung JE, Liu Y, Schultz L, Yasgar A, Perry S, Diaz G, Zhang Q, Kenyon V, Jadhav A, Simeonov A, Lo EH, van Leyen K, Maloney DJ, Holman TR. Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J Med Chem. 2014 May 22;57(10):4035-48. doi: 10.1021/jm401915r. Epub 2014 May 13. PMID: 24684213; PMCID: PMC4033661. 3. Tourki B, Black LM, Kain V, Halade GV. Lipoxygenase inhibitor ML351 dysregulated an innate inflammatory response leading to impaired cardiac repair in acute heart failure. Biomed Pharmacother. 2021 Jul;139:111574. doi: 10.1016/j.biopha.2021.111574. Epub 2021 Apr 13. PMID: 33862495. 4. Cheng G, Zhao W, Xin Y, Huang G, Liu Y, Li Z, Zhan M, Li Y, Lu L, van Leyen K, Liu Y. Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke. J Neurochem. 2021 May;157(3):586-598. doi: 10.1111/jnc.15308. Epub 2021 Feb 5. PMID: 33481248.
In vitro protocol:
1. Hernandez-Perez M, Chopra G, Fine J, Conteh AM, Anderson RM, Linnemann AK, Benjamin C, Nelson JB, Benninger KS, Nadler JL, Maloney DJ, Tersey SA, Mirmira RG. Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. Diabetes. 2017 Nov;66(11):2875-2887. doi: 10.2337/db17-0215. Epub 2017 Aug 25. PMID: 28842399; PMCID: PMC5652601. 2. Rai G, Joshi N, Jung JE, Liu Y, Schultz L, Yasgar A, Perry S, Diaz G, Zhang Q, Kenyon V, Jadhav A, Simeonov A, Lo EH, van Leyen K, Maloney DJ, Holman TR. Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J Med Chem. 2014 May 22;57(10):4035-48. doi: 10.1021/jm401915r. Epub 2014 May 13. PMID: 24684213; PMCID: PMC4033661.
In vivo protocol:
1. Tourki B, Black LM, Kain V, Halade GV. Lipoxygenase inhibitor ML351 dysregulated an innate inflammatory response leading to impaired cardiac repair in acute heart failure. Biomed Pharmacother. 2021 Jul;139:111574. doi: 10.1016/j.biopha.2021.111574. Epub 2021 Apr 13. PMID: 33862495. 2. Cheng G, Zhao W, Xin Y, Huang G, Liu Y, Li Z, Zhan M, Li Y, Lu L, van Leyen K, Liu Y. Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke. J Neurochem. 2021 May;157(3):586-598. doi: 10.1111/jnc.15308. Epub 2021 Feb 5. PMID: 33481248.
Rai et al (2014) Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J.Med.Chem. 57 4035 PMID: 24684213 Rai et al (2014) Discovery of ML351, a potent and selective inhibitor of human 15-lipoxygenase-1. Probe Reports from the NIH Molecular Libraries Program PMID: 24672829